Molnupiravir | Zee News

Advertisement

NewsMolnupiravir

Molnupiravir News

11 Jan 2022

Molnupiravir benefits outweigh risk among Covid patients: Experts

An expert panel of the Central Drugs Standard Control Organisation had recently approved the antiviral Molnupiravir for restricted use in emergency situations, However, ICMR has raised concern over its side effects.

04 Jan 2022

Covid antiviral pill Molnupiravir launched in India, know price, dosage here

The recommended dose of Molnupiravir 800 mg is twice a day for five days The US Food and Drug Administration (USFDA) has also cleared Molnupiravir

29 Dec 2021

Corbevax, Covovax, Molnupiravir: All about India's 3 new COVID19 vaccines

Six COVID-19 vaccines - Serum Institute's Covishield, Bharat Biotech's Covaxin, Zydus Cadila's ZyCoV-D, Russia's Sputnik V and the US-made Moderna and Johnson and Johnson - had already received EUA from the Indian drug regulator earlier.

28 Dec 2021

India gets two more COVID-19 vaccines, CORBEVAX and COVOVAX receive EUA nod

Molnupiravir, an anti-viral drug, has also been approved for restricted use in an emergency situation.

05 Nov 2021

UK approves world's first pill to treat Covid-19. Here's all you need to know

United Kingdom on Thursday became the first country in the world to approve a pill treatment for Covid-19. Developed by Merck and Ridgeback Biotherapeutics the antiviral is called "molnupiravir".

29 Jun 2021

5 Indian pharma companies would jointly conduct a clinical trial of COVID drug

Molnupiravir is an antiviral therapy Merck is developing with Ridgeback Biotherapeutics for the treatment of non-hospitalized COVID-19 patients

06 Dec 2020

COVID-19: New study claims this antiviral drug blocks coronavirus within 24 hr

Researchers have discovered that a new antiviral drug, Molnupiravir, completely suppresses coronavirus transmission within 24 hours. The study was conducted by the research team from Georgia State University (GSU) and was published in the journal Nature Microbiology.

Loading...

NEWS ON ONE CLICK